Study of an HPV treatment vaccine for persistent HPV16/18
Part of Infections clinical trials.
This trial tests a new injection called BBM-C101 for people with a long-lasting HPV16 or HPV18 infection that hasn't gone away with other treatments, or who choose not to have surgery. The goal is to see if the vaccine can help the body clear the virus and prevent precancerous changes from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had HPV16 and/or HPV18 infection for more than 1 year in the cervix, vulva, vagina, or anus.
- You have mild or moderate precancerous changes (CIN, VIN, VAIN, or AIN Grade 2 or less) confirmed by a biopsy within the last 3 weeks.
- You have not had treatment for your HPV-related condition in the past 4 weeks, such as creams, cryotherapy, laser, or surgery.
- You have not received any other HPV treatment vaccine before, but getting a preventive HPV shot (like Gardasil) is okay.
- You are not pregnant, breastfeeding, and agree to use reliable birth control for at least 1 year after the last dose if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental shot, BBM-C101, for women with a specific type of cervical pre-cancer caused by HPV types 16 or 18. The goal is to see if the shot is safe and can help the body fight the infection, possibly eliminating the abnormal cells.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This study tests a new injection (RG002) for women with a cervical precancer called CIN 2 or CIN 3 that is caused by HPV types 16 or 18. The goal is to see if the treatment can help the body clear the precancer without needing surgery.
This trial tests a new vaccine (SYS6026) for women with high-grade cervical lesions caused by HPV type 16 or 18. It aims to see if the vaccine can help the body clear these precancerous cells, potentially avoiding surgery.
Hear when a new HPV16/18 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.